22:07 , Sep 13, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other molecule...
17:02 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays; high throughput screening A high throughput, CRISPR interference (CRISPRi)-based method of mapping genetic interactions could help identify new drug targets for cancer and genetic disorders. The method involves: selecting sgRNAs against genes identified...
18:16 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

IDMC recommends discontinuing Phase III of Axsome's AXS-02 for complex regional pain syndrome

Axsome Therapeutics Inc. (NASDAQ:AXSM) said an IDMC recommended discontinuing for futility the Phase III CREATE-1 trial of once-weekly oral AXS-02 (disodium zoledronate tetrahydrate) for six weeks to treat pain associated with complex regional pain syndrome...
18:02 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

IDMC recommends continuation of Phase III knee OA trial for Axsome's AXS-02

Axsome Therapeutics Inc. (NASDAQ:AXSM) said an IDMC recommended continuing the Phase III COAST-1 trial of AXS-02 (disodium zoledronate tetrahydrate) to treat pain caused by osteoarthritis (OA) of the knee associated with bone marrow lesions following...
07:00 , Sep 2, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Farnesyl diphosphate synthase (FDPS; FPPS) In vitro studies identified non-bisphosphonate FPPS inhibitors that may help treat...
07:00 , Sep 2, 2010 |  BC Innovations  |  Targets & Mechanisms

Going to bis-school

A team at Novartis AG has identified the first non-bisphosphonate inhibitors of farnesyl diphosphate synthase,1 an enzyme targeted by bone-specific bisphosphonates that are approved to treat benign and malignant bone diseases. The researchers believe the...